Nitsan Halevy
Chief Tech/Sci/R&D Officer bij PLURI INC.
Profiel
Nitsan Halevy is currently the Chief Medical Officer at Pluri, Inc. Prior to this, she worked as the Chief Development Officer at Quark Pharmaceuticals, Inc. She holds a doctorate degree from Ben-Gurion University of the Negev.
Actieve functies van Nitsan Halevy
| Bedrijven | Functie | Begin |
|---|---|---|
| PLURI INC. | Chief Tech/Sci/R&D Officer | 01-03-2021 |
Eerdere bekende functies van Nitsan Halevy
| Bedrijven | Functie | Einde |
|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | - |
Opleiding van Nitsan Halevy
| Ben-Gurion University of the Negev | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PLURI INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
